www.99jili

FRISCO, Texas (AP) — Dallas Cowboys linebacker DeMarvion Overshown could miss the 2025 season recovering from the right knee injury sustained in a loss to Cincinnati, coach Mike McCarthy said Tuesday. McCarthy said Overshown has a “long road of rehab in front of him.” The second-year player tore multiple ligaments when a Bengals lineman crashed into his leg in the Cowboys' 27-20 loss Monday night. Overshown missed all of his rookie year in 2023 after tearing the ACL in his left knee in a preseason game. The latest injury came in his first game since a spectacular 23-yard interception return for a touchdown in a 27-20 victory over the New York Giants on Thanksgiving. “DeMarvion is getting ready to have a big surgery in front of him,” McCarthy said of the procedure planned this week. “His physical and football talent speaks for itself. He’s such a bright light. He’s got a great, infectious personality — a tough young man. He is definitely going to be missed.” The former Texas standout, drafted in the third round last year, was second on the team to star pass rusher Micah Parsons with five sacks when he went down. The December timing of Overshown's injury means rehab is likely to extend past training camp and into the regular season next year, after he turns 25. Parsons was emotional when asked about Overshown after the Cincinnati game. “I cried,” he said. “It’s like my little bro, bro. He doesn’t deserve that either. Just to understand what he’s going to go through and to be there for him physically, mentally. It’s just so challenging because of the year he was having. I really just don’t think that’s fair either.” The loss of Overshown comes with defensive end DeMarcus Lawrence close to return from a foot injury that has sidelined him since Week 4. But the Cowboys (5-8) are all but out of the playoffs as they prepare to visit Carolina (3-10) on Sunday. AP NFL: https://apnews.com/hub/nflBiden did the second-guessing as he delivered a speech at the Brookings Institution defending his economic record and challenging Trump to preserve Democratic policy ideas when he returns to the White House next month.

Here's who Trump has picked for his administration so farBOCA RATON, Fla., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Saxena White P.A. issues this notice to update and replace a prior press release issued by Saxena White on December 11, 2024. Plaintiff City of Fort Lauderdale Police and Firefighters’ Retirement System has filed a Notice of Scrivener’s Error with the United States District Court for the Middle District of Tennessee, which attaches a corrected Class Action complaint correcting a typographical error that inadvertently defined the Class Period as beginning on February 8, 2020, whereas the Class Action complaint alleges that the Class Period begins on February 28, 2020. The prior press release issued by Saxena White on December 11, 2024 contained the same typographical error. The Class Action asserts claims on behalf of all persons and entities that purchased or otherwise acquired Acadia Healthcare Company, Inc. securities between February 28, 2020 and October 30, 2024, inclusive. The full, updated press release follows: Saxena White P.A. has filed a securities fraud class action lawsuit (the “Class Action”) in the United States District Court for the Middle District of Tennessee against Acadia Healthcare Company, Inc. (“Acadia Healthcare,” “Acadia,” or the “Company”) (NASDAQ: ACHC) and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder on behalf of all persons and entities that purchased or otherwise acquired Acadia Healthcare securities between February 28, 2020 and October 30, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Saxena White is captioned City of Fort Lauderdale Police and Firefighters’ Retirement System v. Acadia Healthcare Company, Inc., et al ., No. 24-cv-1447 (M.D. Tenn.). The Class Action complaint expands the class period and allegations asserted in a related action against Acadia and certain of its executive officers captioned: Kachrodia v. Acadia Healthcare Company, Inc., et al. , No. 24-cv-1238 (M.D. Tenn. filed Oct. 16, 2024) (the “ Kachrodia Action”). Specifically, the Class Action expands the class period pled from February 28, 2020 to October 18, 2024 in the Kachrodia Action, to February 28, 2020 to October 30, 2024 in the Class Action. Pursuant to the notice published on October 16, 2024 in connection with the filing of the Kachrodia Action, and as required by the Private Securities Litigation Reform Act of 1995 (PSLRA), investors wishing to serve as lead plaintiff are required to file a motion for appointment as lead plaintiff by no later than December 16, 2024. Saxena White’s filing of the Class Action does not alter the lead plaintiff deadline. Based in Franklin, Tennessee, Acadia Healthcare purports to be the leading publicly traded pure-play provider of behavioral healthcare services in the United States. Acadia claims that it is committed to providing communities with high-quality, cost-effective behavioral healthcare services, while growing the Company’s business, increasing profitability, and creating long-term value for shareholders. Most of Acadia’s revenue comes from acute inpatient psychiatric facilities. Acadia receives payments from various payors, including states and the federal government under their respective Medicaid programs. Throughout the Class Period, Defendants touted the quality and safety of Acadia’s inpatient services and the Company’s strong financial performance driven by solid volumes and growth in patient days ( i.e. , length of stay) and same facility revenue. Defendants further touted strong revenue trends driven by rate increases across all payors and positive coverage and reimbursement trends from Medicaid, Acadia’s largest source of revenue. The Class Action alleges that, during the Class Period, the Defendants made materially false and misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects, including that: (1) Acadia admitted patients and held them against their will and beyond the length of time that was medically necessary in order to deceive payors into continuing to pay for such patients’ care; (2) Acadia would not release patients until their insurance ran out; (3) in order to achieve the above, Acadia deployed Company assessors to pressure emergency rooms to send patients to Company facilities, filed frivolous petitions with courts to delay patients’ release, and directed employees to use buzzwords and avoid using other words in patients’ charts to create a false impression of patients’ mental state; (4) Acadia’s admissions, length of stay, and billing practices would subject the Company to government investigations and actions and heightened media scrutiny; (5) in light of such government investigations and actions and media scrutiny, Acadia’s relationships with its referral sources would be negatively impacted; (6) as a result of the above, Acadia experienced slower same-store patient volumes, and in turn, the Company would be forced to lower its full-year 2024 outlook; and (7) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On September 1, 2024, investors began to learn the truth about Acadia’s inpatient services when The New York Times (the “ Times ”) published an article, entitled “How a Leading Chain of Psychiatric Hospitals Traps Patients,” reporting that some of Acadia’s success “was built on a disturbing practice: Acadia has lured patients into its facilities and held them against their will, even when detaining them was not medically necessary.” On this news, the price of Acadia stock fell more than 4.5%, from a closing price of $81.93 per share on August 30, 2024, the prior trading day, to a closing price of $78.21 per share on September 3, 2024, the following trading day. On September 26, 2024, the Times published another article, entitled “Acadia Hospitals Reach $20 Million Settlement With Justice Dept,” reporting that Acadia had agreed to a nearly $20 million settlement with the U.S. Department of Justice, related to an investigation into the Company’s practices of holding “patients for longer than necessary” at its facilities and admitting “people who didn’t need to be there.” On September 27, 2024, Acadia disclosed that it had received a request for information from the U.S. Attorney’s Office for the Southern District of New York and a grand jury subpoena from the U.S. District Court for the Western District of Missouri “related to its admissions, length of stay and billing practices.” On this news, the price of Acadia stock fell more than 16%, from a closing price of $75.66 per share on September 26, 2024, to a closing price of $63.28 per share on September 27, 2024. On October 3, 2024, Acadia received a letter from Adam B. Schiff, Judy Chu, and Julia Brownley, members of the U.S. House of Representatives from California, seeking answers to questions raised by reports “that inpatient psychiatric facilities owned by Acadia Healthcare have wrongfully detained patients under medically unnecessary circumstances.” On this news, the price of Acadia stock fell more than 3.5%, from a closing price of $58.80 per share on October 2, 2024, to a closing price of $56.71 per share on October 3, 2024. On October 18, 2024, the Times published another article entitled “Veterans Dept. Investigating Acadia Healthcare for Insurance Fraud,” reporting that the Veterans Affairs Department is investigating whether Acadia “is defrauding government health insurance programs by holding patients longer than is medically necessary” and “whether Acadia billed insurance programs for patients who were stable enough to be released and did not need intensive inpatient care.” On this news, the price of Acadia stock fell more than 12%, from a closing price of $59.32 per share on October 17, 2024, to a closing price of $52.03 per share on October 18, 2024. The truth was fully revealed on October 30, 2024 when Acadia issued a press release announcing its financial results for the third quarter of 2024. In the press release, Acadia disclosed that it had lowered its full-year 2024 revenue outlook to a range of $3.15 to $3.165 billion and its full-year 2024 adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to a range of $725 to $735 million. During the related earnings call held the next day on October 31, 2024, Chief Financial Officer (CFO) Heather Dixon disclosed that the lowered full-year 2024 guidance was in part due to slower same-store patient day growth of only 3% in the month of October, “which we believe is a result of the recent headlines and reporting in the media.” On this news, the price of Acadia stock fell $9.39 per share, or more than 18%, from a closing price of $52.08 per share on October 30, 2024, to a closing price of $42.69 per share on October 31, 2024. If you purchased Acadia Healthcare securities during the Class Period and were damaged thereby, you are a member of the “Class” and may be able to seek appointment as lead plaintiff. If you wish to apply to be lead plaintiff, a motion on your behalf must be filed with the U.S. District Court for the Middle District of Tennessee no later than December 16, 2024. The lead plaintiff is a court-appointed representative for absent members of the Class. You do not need to seek appointment as lead plaintiff to share in any Class recovery in the Class Action. If you are a Class member and there is a recovery for the Class, you can share in that recovery as an absent Class member. You may contact Marco A. Dueñas ( mduenas@saxenawhite.com ), a Senior Attorney at Saxena White P.A., to discuss your rights regarding the appointment of lead plaintiff or your interest in the Class Action. You also may retain counsel of your choice to represent you in the Class Action. You may obtain a copy of the Complaint and inquire about actively joining the Class Action at www.saxenawhite.com . Saxena White P.A., with offices in Florida, New York, California, and Delaware, is a leading national law firm focused on prosecuting securities class actions and other complex litigation on behalf of injured investors. Currently serving as lead counsel in numerous securities class actions nationwide, Saxena White has recovered billions of dollars on behalf of injured investors. CONTACT INFORMATION Marco A. Dueñas, Esq. mduenas@saxenawhite.com Saxena White P.A. 10 Bank Street, Suite 882 White Plains, New York 10606 Tel.: (914) 437-8551 Fax: (888) 631-3611 www.saxenawhite.com

Financing Solutions for Smart Home Upgrades: Investing in Comfort and SafetyA new training initiative aimed at ensuring culturally safe care for Indigenous patients in Manitoba’s health system was announced Tuesday at the University of Manitoba (UM). The program is called “We Will Take Good Care of the People.” Developed by Ongomiizwin, the Indigenous Institute of Health and Healing at UM’s Rady Faculty of Health Sciences, the program is a partnership with Manitoba’s health organizations. The program, also known as “Giga Mino Ganawenimaag Anishinaabeg” in Anishinaabemowin, draws on the knowledge of Indigenous Knowledge Keepers and health leaders. It will include a variety of activities and reflections to help health workers foster culturally safe environments for Indigenous patients. “The purpose of the training is to address racism, foster culturally safe environments for Indigenous patients, and improve Indigenous health,” said Dr. Marcia Anderson, Vice-Dean of Indigenous Health, Social Justice, and Anti-Racism at the Rady Faculty of Health Sciences. Dr. Anderson said that Indigenous people in Manitoba, who make up 18% of the population, face the poorest health outcomes and the lowest life expectancy. “As an important step toward closing the health gap between Indigenous and non-Indigenous people, we’re providing staff at every level with the foundational knowledge to provide more racially just and culturally safe care.” The training will be available to health-care workers across the province, as well as to faculty and students at the Rady Faculty. It has the capacity to train up to 3,000 people annually, with health employers identifying teams to participate each year. Supported by a nearly $1 million grant from Health Canada’s Addressing Racism and Discrimination in Canada’s Health Systems program, the training will be implemented as a partnership between UM and Manitoba’s health regions. “All health-care workers have a responsibility to understand First Nation, Métis, and Inuit peoples’ rights to culturally safe, equitable, dignified health care,” said Charlene Lafreniere, Provincial lead for Indigenous health at Shared Health. The program’s launch follows other recent pledges to address Indigenous-specific racism in the health system, including apologies from the Canadian Medical Association and the College of Physicians and Surgeons of Manitoba for past and ongoing harms to Indigenous peoples. Culturally safe care training has been offered to Manitoba health workers since 2015, but this is the first comprehensive program developed specifically for the province.